Physician profile
James Grattan
NPI 1841293370
$4,700.03
in general payments reported to CMS, 2019-2025
25 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,600 · 2020: $520 · 2021: $181 · 2022: $417 · 2023: $420 · 2024: $444 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,842.52 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $261.34 | 2021-2025 | |
| Boston Scientific Corporation | $214.20 | 2022-2024 | Watchman Access System |
| Amarin Pharma, INC. | $208.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $191.01 | 2020-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $141.78 | 2020-2022 | |
| Endologix LLC | $121.66 | 2024 | Torus Stent Graft System, Endocross Device |
| Medtronic Vascular, INC. | $109.22 | 2019-2020 | |
| Medtronic, INC. | $102.32 | 2021-2023 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $62.33 | 2022-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $61.49 | 2019-2021 | |
| Abbott Laboratories | $60.34 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Biosense Webster, INC. | $59.15 | 2025 | Carto 3 |
| Philips North America LLC | $49.63 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $44.85 | 2019-2023 | Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.45 | 2024-2025 | Jardiance |
| Pfizer INC. | $32.76 | 2022-2023 | |
| Surmodics, INC. | $21.23 | 2024 | Pounce Venous Thrombectomy System |
| Alnylam Pharmaceuticals INC. | $15.91 | 2019 | |
| Novo Nordisk INC | $15.67 | 2024 | |
| Astellas Pharma US INC | $13.51 | 2019 | |
| Esperion Therapeutics, INC. | $12.35 | 2021 | |
| Gilead Sciences, INC. | $11.67 | 2019 | |
| Merck Sharp & Dohme LLC | $11.41 | 2021 | |
| Bardy Diagnostics, INC. | $0.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Grattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.